3-甲基-1,2,4-噁二唑-5(2H)-酮 | 52386-40-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 3-甲基-1,2,4-噁二唑-5(2H)-酮
• 英文名称: 3-methyl-1,2,4-oxadiazol-5(4H)-one
• 英文别名: 3-Methyl-1,2,4-oxadiazol-5-ol；3-methyl-4H-1,2,4-oxadiazol-5-one
• CAS: 52386-40-0
• 化学式: C₃H₄N₂O₂
• mdl: MFCD09263975
• 分子量: 100.077
• InChiKey: RKRLQDJTVWZXMM-UHFFFAOYSA-N

物化性质

• 熔点：
  62 °C
• 密度：
  1.55±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  7
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  50.7
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  3-甲基-1,2,4-噁二唑-5(2H)-酮 、 2-二乙氨基氯乙烷盐酸盐 在 potassium carbonate 作用下， 以 甲醇 、 丙酮 为溶剂， 生成 4-(2-diethylamino-ethyl)-3-methyl-4H-[1,2,4]oxadiazol-5-one
  参考文献：
  名称：

  Takacs,K.; Harsanyi,K., Chemische Berichte, 1970, vol. 103, p. 2330 - 2335

  摘要：

  DOI：
• 作为产物：
  描述：

  5-benzyloxy-3-methyl-1,2,4-oxadiazole 在 氢氧化钾 作用下， 以 乙醇 为溶剂， 反应 0.17h， 以80%的产率得到3-甲基-1,2,4-噁二唑-5(2H)-酮
  参考文献：
  名称：

  3-取代的1,2,4-恶二唑啉-5-酮; 有用的am前体和保护基

  摘要：

  5-苄氧基-1,2,4-恶二唑和1,2,4-恶二唑啉-5-酮是the部分的有用的前体和保护基团。后者的化合物可以很容易地由ox胺肟制得，也可以通过将腈氧化物环加成到三氯乙腈中并随后水解而制得。氢化后，两个保护基很容易除去，从而释放出母体am。另外，可以将1,2,4-恶二唑啉-5-酮用于N-烷基am的容易的合成。

  DOI：

  10.1016/0040-4039(95)00755-2

文献信息

• Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them
  申请人：Syngenta Limited

  公开号：US20030144263A1

  公开（公告）日：2003-07-31

  Compounds of the formula (I), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolysable ester thereof, 1 wherein, for example, X is —O— or —S—; HET is an optionally substituted C-linked 5-membered heteroaryl ring containing 2 to 4 heteroatoms independently selected from N, O and S; Q is selected from, for example, Q1 and Q2 2 R 2 and R 3 are independently hydrogen or fluoro; T is selected from a range of groups, for example, an N-linked (fully unsaturated) 5-membered heteroaryl ring system or a group of formula (TC5): 3 wherein Rc is, for example, R 13 CO—, R 13 SO 2 — or R 13 CS—; wherein R 13 is, for example, optionally substituted (1-10C)alkyl or R 14 C(O)O(1-6C)alkyl wherein R 14 is optionally substituted (1-10C)alkyl; are useful as antibacterial agents; and processes for their manufacture and pharmaceutical compositions containing them are described.

  式(I)的化合物，或其药学上可接受的盐，或其体内可水解的酯， 其中，例如，X为—O—或—S—； HET是一个可选择的取代的C-连接的含有2到4个异原子（独立选择自N、O和S）的5元杂芳环； Q从Q1和Q2中选择 R2和R3独立地为氢或氟； T从一系列基团中选择，例如，一个N-连接的（完全不饱和的）5元杂芳环系统或式(TC5)的基团： 其中Rc是，例如，R13CO—，R13SO2—或R13CS—； 其中R13是，例如，可选择的取代的(1-10C)烷基或R14C(O)O(1-6C)烷基 其中R14是可选择的取代的(1-10C)烷基；这些化合物可用作抗菌剂；并描述了其制备方法和含有它们的药物组合物。
• [EN] TRICYCLIC INHIBITORS OF HEPATITIS B VIRUS<br/>[FR] INHIBITEURS TRICYCLIQUES DU VIRUS DE L'HÉPATITE B
  申请人：OSPEDALE SAN RAFFAELE SRL

  公开号：WO2020030781A1

  公开（公告）日：2020-02-13

  The present invention relates to compounds that are inhibitors of hepatitis B virus (HBV). Compounds of this invention are useful alone or in combination with other agents for treating, ameliorating, preventing or curing HBV infection and related conditions. The present invention also relates to pharmaceutical compositions containing said compounds.

  本发明涉及抑制乙型肝炎病毒（HBV）的化合物。本发明的化合物可单独使用或与其他药剂结合用于治疗、改善、预防或治愈HBV感染及相关疾病。本发明还涉及含有上述化合物的药物组合物。
• [EN] OCTAHYDRO-CYCLOPENTAPYRROLYL ANTAGONISTS OF CCR2<br/>[FR] ANTAGONISTES OCTAHYDRO-CYCLOPENTAPYRROLYL ANTI-CCR2
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2014014901A1

  公开（公告）日：2014-01-23

  The present invention comprises compounds of Formula (I). Formula (I) wherein: R1, R2, R3, R4, R5, Z1 and Z2 are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).

  本发明包括式(I)的化合物。其中：R1、R2、R3、R4、R5、Z1和Z2如规范中所定义。该发明还包括一种预防、治疗或改善综合症、疾病或疾病的方法，其中所述综合症、疾病或疾病是II型糖尿病、肥胖和哮喘。该发明还包括通过给哺乳动物施用至少一种式(I)化合物的治疗有效量来抑制CCR2活性的方法。
• Synthesis of 2-(2-methyltetrazol-5-yl)-2,2-dinitroacetonitrile and its reaction with substituted nitrile N-oxides
  作者：M. A. Abdelrakhim、A. G. Tyrkov、E. A. Yurtaeva

  DOI：10.1134/s1070428014020237

  日期：2014.2

  A procedure of synthesis of 2-(2-methyltetrazol-5-yl)-2,2-dinitroacetonitrile has been developed and its reaction with substituted nitrile N-oxides has been investigated, proceeding by the mechanism of 1,3-dipolar cycloaddition and affording 2-methyl-5-[(1,2,4-oxadiazol-5-yl)(dinitro)methyl]-2H-tetrazoles. The latter react with KOH in ethanol forming the potassium salt of 2-methyltetrazol-5-yldinitromethane

  的合成的过程2-（2-甲基四唑-5-基）-2,2-二dinitroacetonitrile已经开发和其与腈取代反应Ñ -oxides已经研究了，通过1,3-偶极环加成的机构出发，得到2-甲基-5-[（1,2,4-恶二唑-5-基）（二硝基）甲基] -2 H-四唑。后者与KOH在乙醇中反应，形成2-甲基四唑-5-基二硝基甲烷和取代的5-羟基-1，2，4-恶二唑的钾盐。
• HETEROCYCLIC P2X7 ANTAGONISTS
  申请人：AXXAM S.p.A.

  公开号：EP3398941A1

  公开（公告）日：2018-11-07

  The present invention refers to compounds, and to pharmaceutical compositions containing said compounds, of the following formula (I) or a pharmaceutically acceptable salt thereof: including any stereochemically isomeric form thereof, wherein: R1 is independently selected from the group consisting of aliphatic, aromatic or heteroaromatic ring, optionally substituted by one or more substituents chosen from the group consisting of C1-C4 alkyl optionally substituted by one or more halogen atom(s), halogen, C1-C4 alkoxy; R2 is independently selected from the group consisting of aliphatic, heteroaliphatic, aromatic or heteroaromatic ring, bicyclic aliphatic, heteroaromatic or aromatic ring, C1-C6 alkyl, alkenyl or alkynyl chain, optionally substituted by one or more substituents chosen from the group consisting of C1-C4 alkyl optionally substituted by one or more halogen atom(s), halogen, C1-C4 alkoxy, cyano, C1-C4 alkylthio, SO-C1-C4 alkyl, SO2-C1-C4 alkyl, N(C1-C4 alkyl)2; n is 0, 1 or 2; R3 and R4 can be, independently, -H, -F, C1-C4 alkyl, -OH, -OC1-C4 alkyl; X is O, S, CH2, CH-C1-C4 alkyl, -NH or -NC1-C4 alkyl; R5 is -H or -CH3 optionally substituted by one or more fluorine atoms. The compounds of the invention can be used in treatment of conditions or diseases mediated by P2X7 receptor.

  本发明涉及化合物及含有所述化合物的药物组合物，其化学式为(I)或其药学上可接受的盐：包括其立体化异构体形式，其中：R1独立地选自由由脂肪烃、芳香烃或杂芳环组成的基团，可选择地被来自由由C1-C4烷基、可选择地被一个或多个卤原子取代的卤素、卤素、C1-C4烷氧基的一个或多个取代基替代；R2独立地选自由由脂肪烃、杂脂肪烃、芳香烃或杂芳环、双环脂肪烃、杂芳烃或芳香环、C1-C6烷基、烯基或炔基链组成的基团，可选择地被来自由由C1-C4烷基、可选择地被一个或多个卤原子取代的卤素、卤素、C1-C4烷氧基、氰基、C1-C4烷硫基、SO-C1-C4烷基、SO2-C1-C4烷基、N(C1-C4烷基)2的一个或多个取代基替代；n为0、1或2；R3和R4可以独立地为-H、-F、C1-C4烷基、-OH、-OC1-C4烷基；X为O、S、CH2、CH-C1-C4烷基、-NH或-NC1-C4烷基；R5为-H或-CH3，可选择地被一个或多个氟原子取代。本发明的化合物可用于治疗通过P2X7受体介导的疾病或症状。